Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)

@article{Bialer1999ProgressRO,
  title={Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)},
  author={Meir Bialer and Svein I Johannessen and Harvey J. Kupferberg and Ren{\'e} H Levy and Pierre Loiseau and Emilio Perucca},
  journal={Epilepsy Research},
  year={1999},
  volume={34},
  pages={1-41}
}
The Fourth Eilat Conference on New Antiepileptic Drugs (AEDs) was held at the Royal Beach Hotel, Eilat, Israel, from 6th to 10th September 1998. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss a number of issues in drug development, including outcome assessment in epilepsy (long-term efficacy, quality of life, safety), cost-effectiveness, an update on drugs in development, a progress report on recently marketed AEDs, and controversies in… Expand
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)
TLDR
Information presented on drugs in preclinical and clinical development, including carabersat, CGX-1007 (Conantokin-G), pregabalin, retigabine (D-23129), safinamide, SPD421 (DP-VPA), SPM 927, talampanel and valrocemide are summarized. Expand
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
TLDR
This article summarizes the information presented on drugs in preclinical and clinical development, including AWD 131-138, DP-valproate, harkoseride, LY300164, NPS 1776, NW 1015, pregabalin, remacemide, retigabine, rufinamide and valrocemide. Expand
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
TLDR
This article summarizes the information presented on drugs in development, including atipamezole, BIA-2-093, fluorofelbamate, NPS 1776, pregabalin, retigabine, safinamide, SPM 927, stiripentol, talampanel,ucb 34714 and valrocemide, as well as updates on second-generation AEDs. Expand
Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)
TLDR
Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript. Expand
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
TLDR
This article summarizes the information presented on drugs in development, including brivaracetam, eslicarbazepine acetate, fluorofelbamate, ganaxolone, huperzine, lacosamide, retigabine, rufinamide, seletracetam, stiripentol, talampanel, valrocemide, JZP-4, NS1209, PID and RWJ-333369. Expand
Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X)
TLDR
The Tenth EILat Conference on New Antiepileptic Drugs (AEDs)-EILAT X, took place in Eilat, Israel from the 25th to 29th of April 2010, whose main themes included learning from the past and Detecting assessing and preventing adverse effects of AEDs. Expand
Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)
TLDR
The current (EILAT IX) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development, including brivaracetam, carisbamate, eslicarbazepine acetate and YKP-3089. Expand
New antiepileptic drugs that are second generation to existing antiepileptic drugs
  • M. Bialer
  • Medicine
  • Expert opinion on investigational drugs
  • 2006
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their favourable pharmacokinetics, improved tolerability and lower potentialExpand
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
TLDR
Preclinical and clinical pharmacology of AEDs that are currently in development that include adenosine-releasing silk, allopregnanolone, AMP-X-0079, and twelve novel potential epilepsy treatments are presented for the first time. Expand
An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development
  • K. Jain
  • Medicine
  • Expert opinion on investigational drugs
  • 2000
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference
TLDR
The Third Eilat Conference on New Antiepileptic Drugs was held at the Royal Beach Hotel from May 27 to May 30, 1996 and a summary of the presentations for drugs in development and recent findings on newly marketed drugs is presented. Expand
Progress report on new antiepileptic drugs A summary of the Second Eilat Conference
TLDR
The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994, and concluded with a presentation, 'Still Searching for the Magic Bullet'. Expand
Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
TLDR
Levetiracetam showed a clear antiepileptic effect in the photosensitivity model and appeared to be dose-dependent, the higher the dose the greater the effect; complete abolishment of IPS evoked photoparoxysmal EEG responses was found. Expand
Efficacy and safety of zonisamide: results of a multicenter study
TLDR
The safety and efficacy of zonisamide (ZNS), a new antiepileptic drug, was tested in 167 adult participants who entered a historical-controlled 16-week open label, multicenter study and four persons developed kidney stones and were withdrawn from the study 250-477 days after starting ZNS. Expand
Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic Activity
TLDR
Ganaxolone belongs to a novel class of neuroactive steroids called epalons, which specifically modulate the γ‐aminobutyric acid type A (GABAA) receptor in the central nervous system (CNS). Expand
Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.
TLDR
Tiagabine is a new antiepileptic agent with a novel mechanism of action, which has demonstrated efficacy in the adjunctive treatment of patients with refractory partial epilepsy and its relative merits in relation to other antiePileptic drugs. Expand
Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial.
TLDR
Tiagabine is efficacious and well tolerated as adjunctive therapy for CPS; there is a clear dose-response relationship. Expand
Oxcarbazepine: Mechanisms of Action
TLDR
Blockade of penicillin‐induced epileptiform discharges in hippocampal slices by MHD and its stereoisomers was diminished when the potassium channel blocker 4‐aminopyridine was added to the bath fluid, suggesting that blockade of voltagesensitive sodium channels could contribute to the antiepileptic efficacy of OCBZ. Expand
Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial
TLDR
Zonisamide is an effective antiepileptic drug for add-on treatment of refractory partial epilepsy and was withdrawn in two patients due to adverse events. Expand
Lamotrigine substitution study: evidence for synergism with sodium valproate?
TLDR
The addition of LTG to VPA produced a significantly better response than adding it to CBZ, PHT or PHT, and these data lend credence to the suggestion of therapeutic synergy between LTG and VPA. Expand
...
1
2
3
4
5
...